Takeda stock enters launch phase after FY2026 outlook upgrade

Takeda's first-half results have put new medicines and pipeline execution at the center of its investment case. In a release dated October 29, the Japanese pharmaceutical company said it had raised its FY2026 outlook mainly because of foreign-exchange benefits, while keeping its focus on commercial launches and late-stage development. Takeda's FY2026 first-half results release covers the period from April 1 through September 30, 2026.

New products drive the next phase

Revenue rose 8.4 percent year over year at actual exchange rates, but fell 1.0 percent at constant exchange rates. Core operating profit increased 11.2 percent at actual exchange rates and 0.7 percent at constant exchange rates. The figures show the importance of currency effects in the headline improvement, while underlying growth remained more restrained.

Reported operating profit climbed 60.4 percent, helped by the end of the amortization period for VYVANSE intangible assets and lower impairment charges. Reported net profit increased 171.8 percent to 305.6 billion yen, while adjusted free cash flow fell 38.0 percent to 325.7 billion yen. Core earnings per share rose 10.5 percent at actual exchange rates to 308 yen, but declined 1.2 percent at constant exchange rates.

Takeda highlighted three medicines in its near-term growth plan. ORZEYFUL, or oveporexton, was approved in the United States, Japan and China for narcolepsy type 1 and became available in Japan and China on October 15. Its US commercial launch remained subject to Drug Enforcement Administration scheduling, with the company expecting availability in early November.

MIMRYLO, or rusfertide, launched in the United States in August for erythrocytosis in adults with polycythemia vera. The company also said the US Food and Drug Administration had accepted zasocitinib for Priority Review in moderate-to-severe plaque psoriasis, while the European Medicines Agency was reviewing the application. Zasocitinib remains investigational and requires regulatory approval before commercialization.

Higher forecast, mixed underlying trend

Takeda raised its FY2026 revenue forecast to 4.7 trillion yen from 4.64 trillion yen. Core operating profit guidance increased to 1.19 trillion yen from 1.16 trillion yen, while reported net profit guidance rose to 209.0 billion yen from 166.0 billion yen. Adjusted free cash flow guidance moved to 700.0 billion yen to 800.0 billion yen from 650.0 billion yen to 750.0 billion yen. The annual dividend forecast stayed at 204 yen per share.

At constant exchange rates, management still expects a low-single-digit revenue decline for the year. The revised core operating profit outlook calls for a mid-single-digit decline, compared with the previous guidance of a 5 percent to 8 percent decline. For investors, the distinction between the higher nominal forecast and the weaker constant-exchange-rate trend remains central to assessing the launch strategy.

Takeda President and Chief Executive Officer Julie Kim said the company now needs to translate the product and pipeline milestones into commercial execution. Chief Financial Officer Milano Furuta said transformation savings were being reinvested in launches and research and development. The company intends to use the transformation program, new products and late-stage pipeline to counter pressure from mature and off-patent medicines.

Takeda stock traded at 18.50 euros on Lang & Schwarz at 09:36 CET on Monday, November 9, 2026. The real-time quote of Takeda stock is available in the stock snapshot.

Japan's Nikkei 225 provides the broader market setting for Takeda's home market.

Takeda will hold a Capital Markets Day in Tokyo on December 11, 2026. Investors are likely to focus on the commercial rollout of ORZEYFUL and MIMRYLO, the regulatory path for zasocitinib, transformation savings and the pipeline beyond the company's first strategic horizon.

More news and analyses on Takeda stock will follow the company's product launches, regulatory milestones and longer-term strategy.